Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 9:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: THROMBOLYSIS Clear all
Terminated Phase 3 Interventional

Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery

NCT00338585
View directory record Official record
Conditions
Arterial Occlusive Diseases
Interventions
alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes

NCT00677053
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
TAK-442, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
30 Years to 80 Years
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • Newark, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56

NCT01235351
View directory record Official record
Conditions
Myocardial Infarction, Percutaneous Coronary Intervention
Interventions
Clopidogrel
Drug
Lead sponsor
The TIMI Study Group
Other
Eligibility
18 Years to 75 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Tenecteplase in Patients With COVID-19

NCT04505592
View directory record Official record
Conditions
COVID-19, Respiratory Failure, ARDS
Interventions
Tenecteplase, Placebo
Drug
Lead sponsor
Hooman Poor
Other
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Not applicable Interventional

ULTRAsound-assisted Catheter vs. STAndaRd Catheter Thrombolysis for Submassive Pulmonary Embolism

NCT03389971
View directory record Official record
Conditions
Submassive Pulmonary Embolism
Interventions
catheter-directed thrombolysis
Procedure
Lead sponsor
Piedmont Healthcare
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

NCT01000727
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Darapladib 160 mg, Placebo, Standard Therapy
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
13,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
290
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 252 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 10, 2026, 9:22 AM EDT
Withdrawn Phase 2 Interventional

Phase IIa Venous Thromboembolism (VTE) Prevention Study In Total Knee Replacement (TKR)

NCT00541320
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
GW813893
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
8
States / cities
Birmingham, Alabama • Phoenix, Arizona • Yuba City, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 10, 2026, 9:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Thrombolytic Care During Inter-hospital Transfer

NCT02752256
View directory record Official record
Conditions
Stroke
Interventions
Tissue Plasminogen Activator
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Sep 10, 2026, 9:22 AM EDT
Active, not recruiting Phase 2 Interventional

Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial

NCT05408546
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
TS23, Placebo
Drug
Lead sponsor
Translational Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
13
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 10, 2026, 9:22 AM EDT
Completed No phase listed Observational Results available

Stroke Team Remote Evaluation Using a Digital Observation Camera

NCT00283868
View directory record Official record
Conditions
Stroke
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
4
States / cities
Brawley, California • El Centro, California • San Diego, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Phase 3 Interventional Results available

Tenecteplase in Stroke Patients Between 4.5 and 24 Hours

NCT03785678
View directory record Official record
Conditions
THROMBOLYSIS
Interventions
Tenecteplase, Placebo
Biological · Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
94
States / cities
Birmingham, Alabama • Mesa, Arizona • Anaheim, California + 74 more
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Sep 10, 2026, 9:22 AM EDT
Terminated Phase 1 Interventional Results available

Thrombolysis in Pediatric Stroke (TIPS)

NCT01591096
View directory record Official record
Conditions
Stroke
Interventions
Tissue plasminogen activator (Activase®)
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
2 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Argatroban Stroke Treatment - A Pilot Safety Study

NCT00268762
View directory record Official record
Conditions
Ischemic Stroke
Interventions
argatroban
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 85 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2014 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Not applicable Interventional Results available

Safety Study of Post Intravenous tPA Monitoring in Ischemic Stroke

NCT02039375
View directory record Official record
Conditions
Stroke, Ischemic Stroke
Interventions
"Hopkins" post tPA for ischemic stroke monitoring protocol
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Phase 2 Interventional Results available

Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke

NCT00894803
View directory record Official record
Conditions
Ischemic Stroke, Stroke, Brain Infarction
Interventions
Eptifibatide, rt-PA
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 85 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
20
States / cities
Los Angeles, California • San Diego, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Not applicable Interventional

Safety and Efficacy of Thrombolysis in Combination With Endhole Aspiration in the Treatment of Acute DVT

NCT04297787
View directory record Official record
Conditions
Acute Deep Vein Thrombosis
Interventions
Thrombolysis in combination with endhole aspiration
Device
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Phase 2 Interventional

Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion

NCT00073554
View directory record Official record
Conditions
Arterial Occlusive Diseases, Peripheral Vascular Diseases, Thrombosis
Interventions
Alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 16, 2009 · Synced Sep 10, 2026, 9:22 AM EDT
Completed No phase listed Observational

Long Term Effects of Treating Submassive Pulmonary Embolism With Ultra-sound Accelerated Thrombolysis

NCT01899339
View directory record Official record
Conditions
Submassive Pulmonary Embolism
Interventions
submassive PA treatment with Ekosonic endo device
Other
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Caffeinol Hypothermia Protocol

NCT00299416
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Caffeinol, hypothermia
Drug · Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2011 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Not applicable Interventional Results available

Standard vs Ultrasound-assisted Catheter Thrombolysis for Submassive Pulmonary Embolism

NCT03086317
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Standard Catheter-Directed Thrombolysis, Ultrasound-Accelerated Thrombolysis
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Sep 10, 2026, 9:22 AM EDT
Withdrawn No phase listed Observational

Single Center Post-Market Study of Thrombolytic Therapy Using the Versus™ Catheter

NCT06975969
View directory record Official record
Conditions
Blood Clots, Vascular Disease, Embolism Thrombosis, Cardiovascular Diseases, Lung Diseases
Interventions
Versus™ Endovascular Pulmonary Artery Drug Delivery Catheter
Device
Lead sponsor
Liquet Medical Inc.
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Phase 3 Interventional

Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)

NCT00077792
View directory record Official record
Conditions
Myocardial Infarction, Acute ST-Segment Elevation
Interventions
Enoxaparin sodium (XRP4563)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
20,506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 19, 2009 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Phase 1 Interventional

Safety Study of PP-007 in Subjects With Acute Ischemic Stroke

NCT04677777
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
PP-007 (Two doses administered 24±6 hours apart) + SOC (IVT or MT or IVT+MT)
Biological
Lead sponsor
Prolong Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
8
States / cities
Jacksonville, Florida • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 10, 2026, 9:22 AM EDT
Completed Phase 1 Interventional

A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion

NCT00418483
View directory record Official record
Conditions
Arterial Occlusive Diseases
Interventions
Plasmin (Human) 25 mg, Plasmin (Human) 50 mg, Plasmin (Human) 75 mg, Plasmin (Human) 100 mg, Plasmin (Human) 125 mg, Plasmin (Human) 150 mg, Plasmin (Human) 175 mg
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2016 · Synced Sep 10, 2026, 9:22 AM EDT